Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Unknown 1Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2Head & Neck 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Head and Neck Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Cisplatin 108Radiotherapy 45Docetaxel 44Radiotherapy, Intensity-Modulated 36Gemcitabine 31Fluorouracil 30camrelizumab 24toripalimab 21Drug Therapy 21Cetuximab 20apatinib 19Paclitaxel 16Carboplatin 16pembrolizumab 14Chemoradiotherapy 14Capecitabine 13Blood Specimen Collection 13sintilimab 12nimotuzumab 12Surveys and Questionnaires 10Surgical Procedures, Operative 10Endostatins 10Cyclophosphamide 9nedaplatin 8endostar protein 8durvalumab 8Nivolumab 8Neoadjuvant Therapy 8Induction Chemotherapy 8fludarabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Rosiglitazone × Head & Neck × Clear all
NCT00098852 2014-01-06

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
25 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡